ABIOMED (ABMD) Data Indicates a Coming Beat/Raise - Jefferies

June 30, 2021 8:30 AM EDT Send to a Friend
Jefferies analyst Anthony Petrone reiterated a Buy rating and $425.00 price target on ABIOMED (NASDAQ: ABMD) noting that data through ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login